Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (779)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (779)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- 2018
- Working Paper
Information Provision and Innovation: Natural Experiment of Herbal Patent Prior Art Adoption at the United States and European Patent Offices
By: Prithwiraj Choudhury and Tarun Khanna
We exploit a natural experiment to study how codifying information about prior innovation affects subsequent innovation. A codified database of traditional Indian herbal formulations was adopted by the European Patent Office (EPO) and the U.S. Patent and Trademark... View Details
Keywords: Patents; Plant-Based Agribusiness; Ethnicity; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; China; India
Choudhury, Prithwiraj, and Tarun Khanna. "Information Provision and Innovation: Natural Experiment of Herbal Patent Prior Art Adoption at the United States and European Patent Offices." Harvard Business School Working Paper, No. 14-079, February 2014. (Revised January 2018.)
- December 2010 (Revised April 2012)
- Background Note
Stalemate at the WTO: TRIPS, Agricultural Subsidies, and the Doha Round
By: Arthur A. Daemmrich
This note analyzes disputes over intellectual property enforcement and agricultural trade barriers at the center of the Doha Round of World Trade Organization (WTO) negotiations. Fundamental principles of intellectual property rights and agricultural subsidies are... View Details
Keywords: Agribusiness; Trade; Globalization; Governance; International Relations; Intellectual Property; Agreements and Arrangements; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry
Daemmrich, Arthur A. "Stalemate at the WTO: TRIPS, Agricultural Subsidies, and the Doha Round." Harvard Business School Background Note 711-043, December 2010. (Revised April 2012.)
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
period. Software is penetrating other industries, Kerr notes. Take vaccines. Pharmaceutical companies’ speedy development of mRNA-based vaccines for COVID-19 required software, he notes. “Their capacity to bring a substantial software, AI... View Details
Keywords: by Rachel Layne
- 06 Mar 2012
- First Look
First Look: March 6
influential, and industry less influential, than we commonly assume. How Early Adoption Has Increased Wealth—Until Now Authors:Diego Comin and Bart Hobijn Publication:Harvard Business Review 90, no. 3 (March 2012) Abstract Societies that... View Details
Keywords: Sean Silverthorne
- 24 Jan 2012
- First Look
First Look: Jan. 24
This chapter proposes a new lens to understand corruption, using internal records collected from firms that pay bribes. We examine widespread corruption in three industries in an Asian developing country: procurement, View Details
Keywords: Sean Silverthorne
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- March 2015 (Revised September 2016)
- Case
Terrapin Laboratory
By: Richard G. Hamermesh and Joseph B. Fuller
Describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. The associated teaching materials provide students the opportunity... View Details
Keywords: Business Growth; Entrepreneurial Management; Entrepreneurship; Growth Strategy; Market Entry; Venture Capital; Growth Management; Expansion; Financing and Loans; Health Care and Treatment; Health Testing and Trials; Business Startups; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., and Joseph B. Fuller. "Terrapin Laboratory." Harvard Business School Case 315-098, March 2015. (Revised September 2016.)
- October 2014 (Revised July 2016)
- Supplement
Gilead: Hepatitis C Access Strategy (B)
While the "Gilead: Hepatitis-C Access Strategy (A)" case (HBS No. 515-025) poses questions on what the company should do with respect to hard-hit countries like Egypt and India, the (B) case provides the answer. In both cases, the company chose to pursue a proactive... View Details
Rangan, V. Kasturi. "Gilead: Hepatitis C Access Strategy (B)." Harvard Business School Supplement 515-044, October 2014. (Revised July 2016.)
- January 2014
- Supplement
Amgen Inc.: Pursuing Innovation and Imitation? (B)
By: Ian Mackenzie
The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details
Mackenzie, Ian. "Amgen Inc.: Pursuing Innovation and Imitation? (B)." Harvard Business School Supplement 714-426, January 2014.
- June 2012
- Case
GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships
By: Arthur A. Daemmrich and Ian McKown Cornell
Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details
Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Biotechnology Industry; Brazil
Daemmrich, Arthur A., and Ian McKown Cornell. "GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships." Harvard Business School Case 712-049, June 2012.
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details
Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Biotechnology Industry; Biotechnology Industry; China
Shih, Willy, Sen Chai, Kamen Bliznashki, and Courtney Hyland. "Office of Technology Transfer - Shanghai Institutes for Biological Sciences." Harvard Business School Case 611-057, March 2011. (Revised June 2012.)
- 2010
- Working Paper
Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe
By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details
Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Biotechnology Industry
Liu, Christopher C., and Toby E. Stuart. "Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe." Harvard Business School Working Paper, No. 11-012, August 2010.
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Biotechnology Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- December 2005 (Revised October 2006)
- Case
Pharmacy Service Improvement at CVS (A)
CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems... View Details
Keywords: Information Technology; Performance Improvement; Business Processes; Retail Industry; Retail Industry; United States
McAfee, Andrew P. "Pharmacy Service Improvement at CVS (A)." Harvard Business School Case 606-015, December 2005. (Revised October 2006.)
- January 2005 (Revised March 2006)
- Case
Molecular Insight Pharmaceuticals, Inc.
By: Richard G. Hamermesh and Edwin W. Parkinson III
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing.... View Details
Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)
- April 1993 (Revised May 1994)
- Case
Genzyme Corporation: Strategic Challenges with Ceredase
Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details
Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Biotechnology Industry; Biotechnology Industry; United States
Teisberg, Elizabeth O., and Sharon L. Rossi. "Genzyme Corporation: Strategic Challenges with Ceredase." Harvard Business School Case 793-120, April 1993. (Revised May 1994.)
- May 1992
- Teaching Note
RU 486 (A) and (B), Teaching Note
Teaching Note for (9-391-050) and (9-391-051). View Details
- October 1990 (Revised April 1991)
- Case
RU 486 (A)
Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details
Keywords: Judgments; Ethics; Product Launch; Negotiation; Outcome or Result; Performance; Business and Government Relations; Health Industry; Health Industry; France; Germany; United States
Badaracco, Joseph L., Jr. "RU 486 (A)." Harvard Business School Case 391-050, October 1990. (Revised April 1991.)
- 12 Oct 2006
- First Look
First Look: October 12, 2006
differently than many companies' product development processes, but allows this company to produce very high profit margin products that retain their margins for a very long time in an industry in which products come and go very quickly.... View Details
Keywords: Sean Silverthorne
- July 2005
- Teaching Note
UCB: Managing Information for Globalization and Innovation (A)(TN)
Teaching Note to (9-303-091). View Details